WallStreetZenWallStreetZen

NASDAQ: BIIB
Biogen Inc Stock Forecast, Predictions & Price Target

Analyst price target for BIIB

Based on 16 analysts offering 12 month price targets for Biogen Inc.
Min Forecast
$263.00-12.39%
Avg Forecast
$327.69+9.16%
Max Forecast
$371.00+23.58%

Should I buy or sell BIIB stock?

Based on 16 analysts offering ratings for Biogen Inc.
Buy
Strong Buy
7 analysts 43.75%
Buy
5 analysts 31.25%
Hold
4 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BIIB stock forecasts and price targets.

BIIB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
RBC Capital
Top 2%
99
BuyReiterates$340.00+13.26%2023-06-02
Piper Sandler
Top 24%
77
Strong BuyMaintains$360.00+19.92%2023-06-01Find out why
Wedbush
Bottom 4%
4
HoldReiterates$263.00-12.39%2023-05-23
Argus Research
Top 13%
88
Strong BuyMaintains$350.00+16.59%2023-05-11Find out why
Bank of America
Bottom 10%
10
HoldMaintains$320.00+6.60%2023-05-04
Guggenheim
Bottom 16%
16
Strong BuyUpgrades$350.00+16.59%2023-05-01
Canaccord Genuity
Bottom 10%
10
Strong BuyMaintains$330.00+9.93%2023-04-26
Oppenheimer
Top 2%
99
BuyMaintains$325.00+8.26%2023-04-26
HC Wainwright & Co.
Top 8%
93
BuyReiterates$325.00+8.26%2023-04-26
Barclays
Top 32%
69
HoldMaintains$302.00+0.60%2023-04-26

1 of 2

Forecast return on equity

Is BIIB forecast to generate an efficient return?
Company
N/A
Industry
14.33%
Market
71.95%

Forecast return on assets

Is BIIB forecast to generate an efficient return on assets?
Company
N/A
Industry
5.9%

BIIB earnings growth forecast

How is BIIB forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
-7.25%
Industry
27.44%
Market
25.59%
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BIIB revenue growth forecast

How is BIIB forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
-2.39%
Industry
3.89%
Market
8.44%
BIIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIIB vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
BIIB$300.20$327.69+9.16%Buy
HZNP$99.93$115.20+15.28%Hold
GSK$34.11N/AN/A
GRFS$8.80N/AN/A
OGN$19.76$29.00+46.76%Buy

Biogen Stock Forecast FAQ

Is Biogen Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NASDAQ: BIIB) stock is to Buy BIIB stock.

Out of 16 analysts, 7 (43.75%) are recommending BIIB as a Strong Buy, 5 (31.25%) are recommending BIIB as a Buy, 4 (25%) are recommending BIIB as a Hold, 0 (0%) are recommending BIIB as a Sell, and 0 (0%) are recommending BIIB as a Strong Sell.

If you're new to stock investing, here's how to buy Biogen stock.

What is BIIB's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: BIIB) forecast ROE is N/A, which is considered weak.

What is BIIB's Price Target?

According to 16 Wall Street analysts that have issued a 1 year BIIB price target, the average BIIB price target is $327.69, with the highest BIIB stock price forecast at $371.00 and the lowest BIIB stock price forecast at $263.00.

On average, Wall Street analysts predict that Biogen's share price could reach $327.69 by Jun 2, 2024. The average Biogen stock price prediction forecasts a potential upside of 9.16% from the current BIIB share price of $300.20.

What is BIIB's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: BIIB) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - General industry average of 5.9%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.